AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
HC Wainwright maintains Buy rating for Sagimet Biosciences with $29 PT.
ByAinvest
Thursday, Aug 7, 2025 7:17 am ET1min read
HC Wainwright maintains Buy rating for Sagimet Biosciences with $29 PT.
In a recent update, HC Wainwright has maintained its Buy rating for Sagimet Biosciences Inc. (NASDAQ:SGMT) while raising its price target to $29. This move comes amidst positive developments in the company's pipeline and strategic initiatives.Sagimet Biosciences, a clinical-stage biopharmaceutical company, is focused on developing therapeutics for metabolic and fibrotic disorders. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and a selective fatty acid synthase (FASN) inhibitor. Denifanstat is currently being tested in Phase III clinical trials for moderate to severe acne vulgaris and recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
The upgrade by HC Wainwright reflects the company's potential to capture significant market share in these therapeutic areas. The analyst firm noted that the positive Phase III results for denifanstat in the treatment of moderate to severe acne vulgaris, announced in June 2025, have bolstered the company's prospects. Additionally, the company's participation in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, will provide an opportunity for further insights and updates on its pipeline and strategic initiatives [3].
Sagimet Biosciences has also seen a significant increase in its stock price over the past year, with a 3-year change of +175.24% and a 5-year change of +20.71%. The company's valuation metrics, such as P/E ratio and EV/Sales ratio, indicate strong growth potential. However, it is essential to note that the company's financials show significant net losses, indicating the need for continued investment in research and development.
In conclusion, the upgrade by HC Wainwright to a Buy rating with a $29 price target underscores the potential of Sagimet Biosciences Inc. in the biopharmaceutical sector. The company's strong pipeline and strategic initiatives, coupled with positive clinical trial results, make it an attractive investment opportunity for investors and financial professionals.
References:
[1] https://ca.finance.yahoo.com/news/bofa-raises-amd-price-target-143715127.html
[2] https://www.marketscreener.com/quote/stock/SAGIMET-BIOSCIENCES-INC-156952317/
[3] https://www.quiverquant.com/news/Sagimet+Biosciences+Inc.+to+Participate+in+Canaccord+Genuity+45th+Annual+Growth+Conference+on+August+13%2C+2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet